Format
Sort by
Items per page

Send to

Choose Destination

Best matches for ABL1 and Drug Toxicity:

Search results

Items: 1 to 20 of 58

1.

Dasatinib as an investigational drug for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in adults.

Brattås MK, Reikvam H, Tvedt THA, Bruserud Ø.

Expert Opin Investig Drugs. 2019 May;28(5):411-420. doi: 10.1080/13543784.2019.1597052. Epub 2019 Apr 5. Review.

PMID:
30916583
2.

Insights into the optimal use of ponatinib in patients with chronic phase chronic myeloid leukaemia.

Molica M, Scalzulli E, Colafigli G, Foà R, Breccia M.

Ther Adv Hematol. 2019 Mar 1;10:2040620719826444. doi: 10.1177/2040620719826444. eCollection 2019. Review.

3.

Coexisting driver mutations in MPN: clinical and molecular characteristics of a series of 11 patients.

De Roeck L, Michaux L, Debackere K, Lierman E, Vandenberghe P, Devos T.

Hematology. 2018 Dec;23(10):785-792. doi: 10.1080/10245332.2018.1498182. Epub 2018 Jul 11.

PMID:
29993347
4.

Lenalidomide Induced Toxic Epidermal Necrolysis and Del (5q): Co-occurrence of Rarities.

Chaudhry QUN, Iftikhar R, Satti TM, Mahmood SK, Khan MA, Shahbaz N.

J Coll Physicians Surg Pak. 2018 Jun;28(6):S89-S90. doi: 10.29271/jcpsp.2018.06.S89.

PMID:
29866231
5.

Targeting HSP90 dimerization via the C terminus is effective in imatinib-resistant CML and lacks the heat shock response.

Bhatia S, Diedrich D, Frieg B, Ahlert H, Stein S, Bopp B, Lang F, Zang T, Kröger T, Ernst T, Kögler G, Krieg A, Lüdeke S, Kunkel H, Rodrigues Moita AJ, Kassack MU, Marquardt V, Opitz FV, Oldenburg M, Remke M, Babor F, Grez M, Hochhaus A, Borkhardt A, Groth G, Nagel-Steger L, Jose J, Kurz T, Gohlke H, Hansen FK, Hauer J.

Blood. 2018 Jul 19;132(3):307-320. doi: 10.1182/blood-2017-10-810986. Epub 2018 May 3.

6.

Recent advances in the genomics and therapy of BCR/ABL1-positive and -negative chronic myeloproliferative neoplasms.

Mughal TI, Gotlib J, Mesa R, Koschmieder S, Khoury HJ, Cortes JE, Barbui T, Hehlmann R, Mauro M, Saussele S, Radich JP, Van Etten RA, Saglio G, Verstovek S, Gale RP, Abdel-Wahab O.

Leuk Res. 2018 Apr;67:67-74. doi: 10.1016/j.leukres.2018.02.008. Epub 2018 Feb 14. Review.

PMID:
29466766
7.

JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders.

Vainchenker W, Leroy E, Gilles L, Marty C, Plo I, Constantinescu SN.

F1000Res. 2018 Jan 17;7:82. doi: 10.12688/f1000research.13167.1. eCollection 2018. Review.

8.

Chronic myeloid leukaemia and tyrosine kinase inhibitor therapy: assessment and management of cardiovascular risk factors.

Ross DM, Arthur C, Burbury K, Ko BS, Mills AK, Shortt J, Kostner K.

Intern Med J. 2018 Feb;48 Suppl 2:5-13. doi: 10.1111/imj.13716. Review.

PMID:
29388307
9.

Cardiovascular care of patients with chronic myeloid leukemia (CML) on tyrosine kinase inhibitor (TKI) therapy.

Barber MC, Mauro MJ, Moslehi J.

Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):110-114. doi: 10.1182/asheducation-2017.1.110. Review.

10.

Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial.

Cortes JE, Gambacorti-Passerini C, Deininger MW, Mauro MJ, Chuah C, Kim DW, Dyagil I, Glushko N, Milojkovic D, le Coutre P, Garcia-Gutierrez V, Reilly L, Jeynes-Ellis A, Leip E, Bardy-Bouxin N, Hochhaus A, Brümmendorf TH.

J Clin Oncol. 2018 Jan 20;36(3):231-237. doi: 10.1200/JCO.2017.74.7162. Epub 2017 Nov 1.

11.

An updated review of the JAK1/2 inhibitor (ruxolitinib) in the Philadelphia-negative myeloproliferative neoplasms.

Curto-Garcia N, Harrison CN.

Future Oncol. 2018 Jan;14(2):137-150. doi: 10.2217/fon-2017-0298. Epub 2017 Oct 23.

PMID:
29056075
12.

The Efficacy of Reduced-dose Dasatinib as a Subsequent Therapy in Patients with Chronic Myeloid Leukemia in the Chronic Phase: The LD-CML Study of the Kanto CML Study Group.

Iriyama N, Ohashi K, Hashino S, Kimura S, Nakaseko C, Takano H, Hino M, Uchiyama M, Morita S, Sakamoto J, Sakamaki H, Inokuchi K.

Intern Med. 2018 Jan 1;57(1):17-23. doi: 10.2169/internalmedicine.9035-17. Epub 2017 Oct 16.

13.

Brain Accumulation of Ponatinib and Its Active Metabolite, N-Desmethyl Ponatinib, Is Limited by P-Glycoprotein (P-GP/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2).

Kort A, van Hoppe S, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH.

Mol Pharm. 2017 Oct 2;14(10):3258-3268. doi: 10.1021/acs.molpharmaceut.7b00257. Epub 2017 Sep 19.

PMID:
28880088
14.

Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis.

Giles FJ, Rea D, Rosti G, Cross NCP, Steegmann JL, Griskevicius L, le Coutre P, Coriu D, Petrov L, Ossenkoppele GJ, Mahon FX, Saussele S, Hellmann A, Koskenvesa P, Brümmendorf TH, Gastl G, Castagnetti F, Vincenzi B, Haenig J, Hochhaus A.

J Cancer Res Clin Oncol. 2017 Aug;143(8):1585-1596. doi: 10.1007/s00432-017-2402-x. Epub 2017 Mar 31.

15.

In vitro and in vivo evaluation of dasatinib and imatinib on physiological parameters of pulmonary arterial hypertension.

Baumgart B, Guha M, Hennan J, Li J, Woicke J, Simic D, Graziano M, Wallis N, Sanderson T, Bunch RT.

Cancer Chemother Pharmacol. 2017 Apr;79(4):711-723. doi: 10.1007/s00280-017-3264-2. Epub 2017 Mar 10.

PMID:
28283735
16.

Codelivery of Ponatinib and SAR302503 by Active Bone-Targeted Polymeric Micelles for the Treatment of Therapy-Resistant Chronic Myeloid Leukemia.

Mu CF, Xiong Y, Bai X, Sheng YJ, Cui J.

Mol Pharm. 2017 Jan 3;14(1):274-283. doi: 10.1021/acs.molpharmaceut.6b00872. Epub 2016 Dec 13.

PMID:
27957861
17.

Second line small molecule therapy options for treating chronic myeloid leukemia.

Molica M, Massaro F, Breccia M.

Expert Opin Pharmacother. 2017 Jan;18(1):57-65. doi: 10.1080/14656566.2016.1267141. Epub 2016 Dec 9. Review.

PMID:
27901368
18.

The Myocyte-Damaging Effects of the BCR-ABL1-Targeted Tyrosine Kinase Inhibitors Increase with Potency and Decrease with Specificity.

Hasinoff BB, Patel D, Wu X.

Cardiovasc Toxicol. 2017 Jul;17(3):297-306. doi: 10.1007/s12012-016-9386-7.

PMID:
27696211
19.

Discovery and characterization of a novel potent type II native and mutant BCR-ABL inhibitor (CHMFL-074) for Chronic Myeloid Leukemia (CML).

Liu F, Wang B, Wang Q, Qi Z, Chen C, Kong LL, Chen JY, Liu X, Wang A, Hu C, Wang W, Wang H, Wu F, Ruan Y, Qi S, Liu J, Zou F, Hu Z, Wang W, Wang L, Zhang S, Yun CH, Zhai Z, Liu J, Liu Q.

Oncotarget. 2016 Jul 19;7(29):45562-45574. doi: 10.18632/oncotarget.10037.

20.

Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial.

Lipton JH, Chuah C, Guerci-Bresler A, Rosti G, Simpson D, Assouline S, Etienne G, Nicolini FE, le Coutre P, Clark RE, Stenke L, Andorsky D, Oehler V, Lustgarten S, Rivera VM, Clackson T, Haluska FG, Baccarani M, Cortes JE, Guilhot F, Hochhaus A, Hughes T, Kantarjian HM, Shah NP, Talpaz M, Deininger MW; EPIC investigators.

Lancet Oncol. 2016 May;17(5):612-21. doi: 10.1016/S1470-2045(16)00080-2. Epub 2016 Apr 12.

PMID:
27083332

Supplemental Content

Loading ...
Support Center